Tema Oncology ETF (NASDAQ:CANC) Sees Large Decline in Short Interest

Tema Oncology ETF (NASDAQ:CANC) was the recipient of a significant drop in short interest in September. As of September 30th, there was short interest totaling 3,300 shares, a drop of 73.4% from the September 15th total of 12,400 shares. Based on an average daily trading volume, of 8,200 shares, the short-interest ratio is currently 0.4 days. Based on an average daily trading volume, of 8,200 shares, the short-interest ratio is currently 0.4 days.

Tema Oncology ETF Trading Down 0.1%

NASDAQ:CANC opened at $30.13 on Monday. The company’s 50-day moving average price is $27.70 and its 200-day moving average price is $25.68. Tema Oncology ETF has a twelve month low of $20.10 and a twelve month high of $30.64. The company has a market cap of $84.06 million, a P/E ratio of 20.39 and a beta of 1.11.

Hedge Funds Weigh In On Tema Oncology ETF

Institutional investors have recently bought and sold shares of the company. Banque Transatlantique SA purchased a new position in Tema Oncology ETF during the first quarter worth about $39,000. Jane Street Group LLC purchased a new position in Tema Oncology ETF during the first quarter worth about $213,000. Finally, Thrivent Financial for Lutherans raised its stake in Tema Oncology ETF by 658.7% during the second quarter. Thrivent Financial for Lutherans now owns 957,475 shares of the company’s stock worth $23,673,000 after purchasing an additional 831,281 shares during the period.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.